Biochem Pharma succeeds in invalidating Emory University's Australian patent application relating to 3TC.
This decision is in line with the European Patent Office Opposition Division's recent decisions dismissing Emory oppositions against BioChem Pharma's pioneering patents covering compositions of matter for a wide range of nucleoside analogues (European Patent 337 713) and 3TC (European Patent 382 526).
Francesco Bellini, chief executive officer, BioChem Pharma, said, ``We are very pleased that the Australian Patent Office has agreed with BioChem's position that the Emory Australian patent application is invalid. This latest decision by the Australian Patent Office joins the European Patent Office decisions upholding what we have consistently maintained - we are the sole and true inventors of 3TC."
BioChem Pharma is an international biopharmaceutical company dedicated to the research, development and commercialization of innovative products for the prevention, detection and treatment of human diseases with a focus in the anticancer and anti-infective areas.
3TC is a trademark of the Glaxo Wellcome (London, United Kingdom) group of companies.
|Printer friendly Cite/link Email Feedback|
|Comment:||Biochem Pharma succeeds in invalidating Emory University's Australian patent application relating to 3TC.|
|Publication:||BIOTECH Patent News|
|Date:||Aug 1, 1999|
|Previous Article:||Cortex to receive additional claims for enhancement of neurotrophic factor expression.|
|Next Article:||Kinetek Pharmaceuticals awarded patent for KP-102, orally active type 2 diabetes therapy.|